Skip to main content
. Author manuscript; available in PMC: 2017 May 28.
Published in final edited form as: Oncogene. 2016 Nov 28;36(20):2791–2801. doi: 10.1038/onc.2016.439

Figure 1. Silencing MUC1-C downregulates BMI1 expression.

Figure 1

A–C. BT-549 cells were stably transduced to express a tetracycline-inducible control shRNA (tet-CshRNA) (A) or a MUC1 shRNA (tet-MUC1shRNA) (B). Cells treated with 200 ng/ml DOX for 4 d were analyzed for MUC1 and BMI1 mRNA levels by qRT-PCR. The results (mean±SD) are expressed as relative mRNA levels compared to that obtained for control DOX-untreated cells (assigned a value of 1). Cell lysates treated with 200 ng/ml DOX for 7 d were immunoblotted with the indicated antibodies (C). D. MDA-MB-231/tet-MUC1shRNA cells treated with 200 ng/ml DOX for 4 d were analyzed for MUC1 and BMI1 mRNA levels by qRT-PCR (left). Cell lysates treated with 200 ng/ml DOX for 7 d were immunoblotted with the indicated antibodies (right). E. BT-20 cells stably expressing a control or MUC1-C vector were analyzed for BMI1 mRNA levels by qRT-PCR. The results (mean±SD) are expressed as relative BMI1 mRNA levels compared to that obtained for vector cells (assigned a value of 1) (left). Lysates were immunoblotted with the indicated antibodies (right).